Biological characterization of chemically diverse compounds targeting the  coenzyme A synthesis pathway by unknown
RESEARCH Open Access
Biological characterization of chemically
diverse compounds targeting the
Plasmodium falciparum coenzyme A
synthesis pathway
Sabine Fletcher1†, Leonardo Lucantoni1†, Melissa L. Sykes1, Amy J. Jones1, John P. Holleran1, Kevin J. Saliba2
and Vicky M. Avery1*
Abstract
Background: In the fight against malaria, the discovery of chemical compounds with a novel mode of action and/
or chemistry distinct from currently used drugs is vital to counteract the parasite’s known ability to develop drug
resistance. Another desirable aspect is efficacy against gametocytes, the sexual developmental stage of the parasite
which enables the transmission through Anopheles vectors. Using a chemical rescue approach, we previously
identified compounds targeting Plasmodium falciparum coenzyme A (CoA) synthesis or utilization, a promising
target that has not yet been exploited in anti-malarial drug development.
Results: We report on the outcomes of a series of biological tests that help to define the species- and stage-
specificity, as well as the potential targets of these chemically diverse compounds. Compound activity against
P. falciparum gametocytes was determined to assess stage-specificity and transmission-reducing potential. Against
early stage gametocytes IC50 values ranging between 60 nM and 7.5 μM were obtained. With the exception of
two compounds with sub-micromolar potencies across all intra-erythrocytic stages, activity against late stage
gametocytes was lower. None of the compounds were specific pantothenate kinase inhibitors. Chemical rescue
profiling with CoA pathway intermediates demonstrated that most compounds acted on either of the two final
P. falciparum CoA synthesis enzymes, phosphopantetheine adenylyltransferase (PPAT) or dephospho CoA
kinase (DPCK). The most active compound targeted either phosphopantothenoylcysteine synthetase (PPCS) or
phosphopantothenoylcysteine decarboxylase (PPCDC). Species-specificity was evaluated against Trypanosoma
cruzi and Trypanosoma brucei brucei. No specific activity against T. cruzi amastigotes was observed; however
three compounds inhibited the viability of trypomastigotes with sub-micromolar potencies and were confirmed
to act on T. b. brucei CoA synthesis.
Conclusions: Utilizing the compounds we previously identified as effective against asexual P. falciparum, we
demonstrate for the first time that gametocytes, like the asexual stages, depend on CoA, with two compounds
exhibiting sub-micromolar potencies across asexual forms and all gametocytes stages tested. Furthermore, three
compounds inhibited the viability of T. cruzi and T. b. brucei trypomastigotes with sub-micromolar potencies and
were confirmed to act on T. b. brucei CoA synthesis, indicating that the CoA synthesis pathway might represent a
valuable new drug target in these parasite species.
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Background
Malaria is a tropical infectious disease caused by
intracellular apicomplexan parasites of the genus
Plasmodium, which are transmitted to the human host
during the blood meal of an infected female Anopheles
mosquito. Half of the world’s population is at risk of
contracting the disease and over 200 million cases are
reported annually, of which more than 400,000 are fatal
[1]. Malaria is curable and a dramatic reduction in mor-
tality rates has been achieved in the last decade, thanks
to sustained efforts by multiple donor agencies and the
WHO [2]. However, the development of parasite
resistance to chemotherapeutics remains a major con-
cern. Resistance against classic antimalarials, such as
chloroquine and pyrimethamine, is widespread and has
severely reduced the efficacy of these drugs [3]. Alarm-
ingly, development of resistance against the current drug
of choice, artemisinin, which is the core compound of
the widely used artemisinin combination therapies
(ACT), has recently been reported in four Southeast
Asian countries and appears to be spreading [4, 5]. To
prevent a lack of effective therapeutics in the future, new
anti-malarial compounds, ideally acting on different tar-
gets and/or displaying novel mechanisms of action, ur-
gently need to be identified and developed [3, 6].
Coenzyme A (CoA) plays a central role in eukaryotic
metabolism as an acyl carrier. Its acetylated form, acetyl-
CoA, enters the tricarboxylic acid (TCA) cycle, a central
metabolic hub. It serves as a vital co-factor for fatty acid
synthesis [7], as well as pyruvate and fatty acid oxidation
[8] for energy production in the form of ATP [9]. CoA is
synthesized in five enzymatic steps (Fig. 1) from units de-
rived from pantothenic acid (vitamin B5), ATP and cyst-
eine. Pantothenate kinase (PanK) catalyses the first step of
the Plasmodium falciparum CoA synthesis pathway, phos-
phorylation of pantothenate to 4′-phosphopantothenate.
In the second synthesis step, an L-cysteine molecule is inte-
grated by phosphopantothenoylcysteine synthetase (PPCS)
and the resulting intermediate, 4′- phosphopantothenoyl-
cysteine, is decarboxylated to 4′-phosphopantetheine by
the third enzyme, phosphopantothenoylcysteine decarb-
oxylase (PPCDC). Phosphopantetheine adenylyltransferase
(PPAT) catalyses the penultimate step of the synthesis, con-
verting 4′-phosphopantetheine into dephospho-CoA (dP-
CoA). The final phosphorylation step that completes CoA
synthesis is catalyzed by dP-CoA kinase (DPCK). In
humans, this enzyme is not a single entity but is linked to
phosphopantetheine adenylyltransferase (PPAT) to form a
bifunctional enzyme that can be regarded as a CoA syn-
thetase [10]. Despite conservation of function, the cod-
ing sequences of the enzymes involved in CoA synthesis
are not highly conserved between eukaryotic species
[11] and the essentiality of several of the P. falciparum
enzymes has been predicted in two independent in silico
studies based on metabolic network analysis [12, 13].
This fact presents an opportunity to target specifically
the P. falciparum CoA synthesis pathway for the devel-
opment of novel antimalarial drugs.
In 2005, pantothenol (provitamin B5) was identified as
an inhibitor of P. falciparum growth [14]. It was shown
to interact with pantothenate kinase (PanK) and its
mechanism of action attributed to an effect on CoA syn-
thesis or utilization [14]. Subsequent work also demon-
strated that intra-erythrocytic P. falciparum is capable of
de novo CoA synthesis, consistent with parasite survival
being independent of host CoA biosynthesis [15]. The
investigation of a series of pantothenate analogues re-
vealed several compounds with modest anti-plasmodial
activity [16]. Recently, pantothenamides (secondary or
tertiary amides of pantothenic acid) were shown to in-
hibit P. falciparum proliferation with sub-micromolar
activity, but only when the serum enzyme pantetheinase
Fig. 1 Enzymatic steps of the P. falciparum CoA synthesis pathway. Abbreviations: PanK, pantothenate kinase; PPCS, phosphopantothenoylcysteine
syntetase; PPCDC, phosphopantothenoylcysteine decarboxylase; PPAT, pantetheinephosphate adenylyltransferase; DPCK, dephospho coenzyme A kinase
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is inhibited [17]. Currently, different strategies are being
developed to overcome pantetheinase-mediated degrad-
ation of pantothenamides, thereby improving the activity
of this group of pantothenic acid analogs in vivo [18–21].
Utilizing an alternative approach, rather than chem-
ically modifying a specific substrate of the CoA synthesis
pathway, we recently developed a CoA chemical rescue
screening approach to identify novel, chemically diverse
inhibitors of the CoA pathway in asexual blood stage P.
falciparum [22]. Supplementing the parasite culture
medium with CoA allowed asexual P. falciparum forms
to survive the anti-plasmodial effect of eleven
chemically-diverse inhibitors, consistent with these
compounds inhibiting CoA synthesis or utilization. The
inhibitors were identified from two small chemical
compound libraries, one in-house library and the Medi-
cines for Malaria Venture (MMV) Malaria Box [23]. In
this study we report the further characterization of the
stage- and species-specificity of the compounds that
showed the most prominent rescue by CoA in our pre-
vious report. Firstly, stage specificity was assessed on
gametocytes, the sexual stages of P. falciparum, which
emerge among the intra-erythrocytic population and
develop over 10–12 days into 5 morphologically differ-
ent stages (I to V) [24]. Gametocytes are essential for
inter-host transmission of malaria [25]. Previous re-
search demonstrated that gametocyte stages show re-
markable differences to the asexual blood stages of the
parasites at the cellular, transcriptional and metabolic
levels [25–28], and in their sensitivity to antimalarial
drugs [29, 30]. Secondly, the species-specificity was
assessed using two other protozoan parasites, namely
Trypanosoma cruzi and Trypanosoma brucei brucei. Po-
tential targets of the compounds were examined through
assessment of parasite growth rescue patterns after sup-
plementation with different CoA pathway intermediates.
Results
Compound activity on Plasmodium falciparum sexual
development stages
Compound activity against early and late stage gametocytes
All test compounds displayed gametocytocidal activity.
Similar IC50 activities were observed on early stage game-
tocytes to those previously reported for the asexual blood
stage forms of the parasite (Additional file 1: Table S1).
The IC50 values obtained for the compounds against early
stage gametocytes ranged between 60 nM and 7.5 μM, with
four compounds displaying sub-micromolar activity
(Additional file 1: Table S1). Against the later stages (IV and
V) of gametocyte development, three compounds showed
significantly reduced activity compared to both asexual
stages and early stage gametocytes (Additional file 1:
Table S1). Compounds Amb4317088, STK 668036 and
MMV665980 displayed moderate, single digit micromolar
activity against all development stages tested. Very prom-
ising results were obtained for STK 740987 and
Amb180780, which had sub-micromolar IC50 values on all
three P. falciparum developmental stages investigated
(Additional file 1: Table S1). The IC50 range for STK
740987 was 0.38–0.46 μM across all P. falciparum life-
cycle stages tested, with an overall SI over human embry-
onic kidney cells (HEK293) above 94. The IC50 range for
Amb180780 was 0.06–0.12 μM across the tested life-cycle
stages, with overall HEK293 SI > 482.
Gametocyte-infected red blood cell deformability
The lipid composition of the RBC membrane can influ-
ence the deformability of the cell, as observed under
treatment with 3-hydroxy-3-methylglutaryl CoA reduc-
tase (HMG-CoA reductase) inhibitors such as simva-
statin, pravastatin and lovastatin [31–33]. Since CoA
plays a vital role in the synthesis and oxidation of fatty
acids in general [9] and is furthermore directly required
for the synthesis of 3-hydroxy-3-methylglutaryl-CoA, the
main substrate of HMG-CoA reductase, we were inter-
ested in investigating whether any of the CoA synthesis
inhibitors demonstrating late stage gametocytocidal ac-
tivity would exhibit an effect on RBC deformability. The
ability of late stage gametocyte-infected RBC to cross a
spleen mimic was assessed using an optimised micro-
sphere filtration assay based on a recently published ap-
proach [34]. The retention of gametocyte-infected RBCs
was determined after treatment for 2 or 24 h with com-
pound concentrations ranging from 0.1 nM to 10 μM.
Since dead parasites also display a higher retention rate
in the filtration assay, the viability of the compound-
treated gametocytes was assessed simultaneously using
MitoTracker ® Red staining and confocal microscopy.
No increased retention of late stage gametocytes in
the spleen mimic were observed that did not coincide
with parasite death for any of the test compounds.
Therefore, no specific deformability changes, inde-
pendent of gametocytocidal activity, could be deter-
mined for the CoA synthesis inhibitors examined
(Additional file 1: Figure S1).
Compound activity against Trypanosoma cruzi and
Trypanosoma brucei brucei
The next step taken was to determine whether the activ-
ity of the compounds was confined to P. falciparum, or
whether it extended to other protozoan parasites. Com-
pound activity against two members of another clinically
important group of parasites, the kinetoplastids T. cruzi
and T. b. brucei was determined. The sensitive high con-
tent imaging assay used to determine compound activity
against T. cruzi assesses the intracellular amastigote life
form of the parasite in the 3T3 host cell [35]. It is im-
portant to simultaneously assess compound activity
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against 3T3 cells to determine potential cytotoxicity
against the host cell line, since this could result in a false
positive outcome. The T. b. brucei assay employs the
REDOX indicator Alamar Blue to assess viability, which
was developed into a 384-well assay format [36].
The activity of the MMV malaria box compounds
(MMV665820 and MMV665980) against T. b. brucei
and T. cruzi has previously been reported in ChEMBL
[37]. In our models, none of the compounds tested
showed appreciable selectivity against T. cruzi amasti-
gotes, compared to the 3T3 host cell line (Additional
file 1: Table S1).
Trypanosoma brucei brucei causes African trypano-
somiasis in animals and is not infective to humans.
However, it is closely related to the human infective
species T. brucei gambiense and T. brucei rhodesiense
and is widely used as a surrogate organism to investigate
anti-trypanosomal compound activity. As T. b. brucei
trypomastigotes are extracellular blood stream parasites,
no direct host cell comparison is required. As opposed
to the negative outcome obtained with T. cruzi, several
of the compounds investigated showed activity against
T. b. brucei. Three compounds, namely STK 740987,
Amb3377585 and Amb4317088, had very promising ac-
tivities with IC50 values as low as 1 μM, 200 nM and 160
nM, respectively (Additional file 1: Table S1), and one
compound (MMV665820) was moderately active with
an IC50 value of 2.5 μM. STK 740987 demonstrates a
good selectivity index of > 39 for T. b. brucei compared
to HEK293 cells. The selectivity indices of Amb4317088
and Amb3377585 are also promising, with values of 15
and 14, respectively (Additional file 1: Table S1).
The higher activity of the compounds against T. b.
brucei, as opposed to the generally low activity observed
on T. cruzi amastigotes, prompted us to investigate
whether this discrepancy was due to species specific dif-
ferences or due to the different trypanosome life forms
used in the respective assays. Testing of the compounds
in our recently developed T. cruzi trypomastigote assay
[35], revealed higher compound activities against the
extracellular trypomastigote form (Additional file 1:
Table S1). The three most active compounds
Amb4317088, STK 740987 and Amb3377585 dis-
played sub-micromolar IC50 values against T. cruzi
trypomastigotes [0.392 μM, 0.682 μM and 0.744 μM,
respectively (Additional file 1: Table S1)].
Target investigation within the coenzyme A synthesis
pathway
After the assessment of the broader biological activity
profiles of the candidate compounds, we endeavored to
identify if specific steps within the CoA synthesis path-
way were affected by the inhibitors. To this end, we
assessed a possible direct inhibition of the first enzyme
of the pathway, PanK. Subsequently, given the current
lack of direct enzymatic assays to measure the inhibition
of the following biosynthetic steps, several metabolites
of the pathway were tested on each parasite species and/
or stage that had shown susceptibility to the experimen-
tal compounds, to ascertain if they could rescue the
growth inhibitory effect caused by the compounds. Para-
sites were treated with the test compounds at their re-
spective IC80 concentrations in the presence or absence
of either pantothenate, pantethine, dP-CoA or CoA.
Pantothenate is the first substrate of the pathway
(Fig. 1) and its addition was intended to rescue the ac-
tion of possible competitive inhibitors of the first en-
zyme, PanK. Such a competitive inhibitory effect has
previously been demonstrated for a number of panto-
thenate analogues, including pantothenol [16], herein
used as a positive control compound for this assay. Pan-
tethine is the dimer of pantetheine and not a direct
intermediate of the pathway. It is known that bacteria
are able to convert pantethine to pantetheine and to
subsequently phosphorylate it to 4′phosphopantetheine,
the substrate of PPAT, the fourth enzyme in the pathway
(Fig. 1) [38]. It is not known, whether P. falciparum is
capable of pantetheine phosphorylation for utilization in
CoA synthesis. It was anticipated that if pantethine
could be taken up by the parasite, reduced to pan-
tetheine and then phosphorylated, pantethine would
allow the parasites to bypass inhibition caused by inhibi-
tors of the first three enzymes, namely PanK, PPCS and
PPCDC. This possibility was investigated by testing
whether pantethine was able to rescue the growth in-
hibitory effect of any of the inhibitors. Finally, the rescue
ability of dP-CoA, the final substrate of CoA synthesis,
was tested. Supplementation of dP-CoA was assumed to
be able to rescue inhibition of any of the enzymatic
steps, except for the final one (Fig. 1), allowing the
identification of non-competitive DPCK inhibitors and
downstream CoA utilizing enzymes, as such compounds
are the only ones whose inhibition would not be rescued
by dP-CoA. Inhibitors competing with dP-CoA for
DPCK binding were expected to be displaced, thereby
rescuing parasite survival, by dP-CoA supplementation
in a concentration dependent manner.
Pantothenate kinase inhibition
A radiometric assay, which allows measurement of the
phosphorylation of various substrates by kinases present
in P. falciparum lysates [16, 39], was used to test the
effect of the chemical compounds of interest at 100 μM
concentration on PanK activity. Only one compound,
STK 668036, showed a statistically significant PanK
inhibition (93 ± 9%; Additional file 1: Figure S2a). This
compound was also tested at three concentrations (2, 10
and 100 μM) in parallel against P. falciparum PanK and
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the two CoA-pathway unrelated P. falciparum kinases,
hexokinase (HK) and choline kinase (ChK). None of the
investigated kinases were inhibited significantly at 2 μM,
a concentration that is active in whole cell assays. At
10 μM, STK 668036 inhibited HK by 40 ± 2% (t-test t =
10.47, df = 10, P < 0.0001) and at 100 μM it showed sig-
nificant 105 ± 1%, 84 ± 4% and 28 ± 8% inhibition on HK,
PanK and ChK, respectively (ANOVA: F(3,15) = 296.4, P <
0.001; Additional file 1: Figure S2b).
Rescue of CoA pathway metabolites in P. falciparum
asexual stages
The asexual blood stage inhibitory activity of the com-
pounds was compared with the activity obtained in the
presence of the CoA biosynthesis pathway metabolites.
The most active compound on asexual P. falciparum,
Amb180780, was rescued to approximately 100% of con-
trol levels by supplementation of dP-CoA or CoA and to
76 ± 8% by pantethine addition (ANOVA: F(4,15) =
145.2, P < 0.001), but not by pantothenate (Additional
file 1: Table S2). This rescue pattern is consistent with
the target of Amb180780 being either PPCS or PPCDC.
Our pantothenate kinase assay (see above) did not reveal
inhibition of PanK, thus suggesting that the compound
is not a non-competitive inhibitor of PanK.
The growth inhibitory action of all the remaining
compounds was rescued by supplementation of either
dP-CoA or CoA, but not pantothenate or pantethine
(Additional file 1: Table S2). This is consistent with the
target of these compounds being towards the end of the
CoA synthesis chain, namely inhibition of PPAT or com-
petitive inhibition of DPCK. An alternative hypothesis
could be competitive inhibition of some yet unidentified,
downstream enzymes that utilize CoA. Supplementing
additional CoA might overcome the competitive inhib-
ition by the compound and thus restore function. The
growth inhibitory effect of MMV000570 at 1 μM con-
centration could not effectively be rescued by any of the
intermediates in this study. Since we were unable to re-
produce the CoA rescue we previously observed for this
compound [22], the compound’s activity is not discussed
further, however all data for this compound can be
found in the supplementary data section (Additional
file 1: Table S3).
Rescue of CoA pathway metabolites in sexual P. falciparum
stages
The ability of the metabolites to rescue the parasites
from compound-mediated inhibition was then deter-
mined for early stage gametocytes for the compounds
that had displayed sub-micromolar activity. The most
active compound, Amb180780 (early gametocyte IC50 =
60 nM), was rescued to near 100% (ANOVA: F(3,12) =
605.4, P < 0.0001; Tukey’s multiple comparisons test P <
0.001) of control levels by addition of pantethine, dP-
CoA and CoA, supporting the observation with asexual
stages that the compound is a PPCS or PPCDC inhibitor
(Additional file 1: Table S2).
The rescue pattern for MMV665820 and Amb
3377585 showed that their activity could only be
counteracted by supplementation of dP-CoA and
CoA (ANOVA: F(2,9) = 65.66, P < 0.0001 and F(2,9) =
75.44, P < 0.0001, respectively; Tukey’s multiple com-
parisons test P < 0.001 for both), confirming our find-
ing in asexual blood stage P. falciparum. The most
likely targets for these two compounds are therefore
PPAT or competitive inhibition of DPCK (Additional
file 1: Table S2).
STK 740987-treated early stage gametocytes (IC50 =
430 nM) showed low, albeit statistically significant levels
of 23 ± 1% and 24 ± 1% rescue under dP-CoA and CoA
supplementation (ANOVA: F(2,13) = 441.5, P < 0.0001;
Tukey’s multiple comparisons test P < 0.001), respect-
ively, and were not rescued by the other intermediates
(Additional file 1: Table S2). Since this compound
showed high activity (> 95%) at its previously deter-
mined IC80 value, the rescue experiment was repeated
whilst reducing the test concentrations to its IC50 value.
This resulted in higher rescue levels of 46 ± 2% and 62 ±
1% under dP-CoA and CoA supplementation (ANOVA:
F(2,9) = 37.95, P < 0.001), respectively, whilst compound
action remained unaffected by supplementation of
pantothenate and pantethine. The observed rescue pat-
tern indicates that this compound acts either on PPAT
or as a competitive inhibitor of DPCK (Additional file 1:
Table S2), although it might possess additional,
gametocyte-specific target(s) outside the CoA synthesis
pathway that can therefore not be rescued by CoA
metabolites.
For the three most active compounds identified for
late stage gametocytes, Amb4317088 (IC50 = 2.2 μM),
STK740987 (IC50 = 460 nM) and Amb180780 (IC50 = 70
nM), the rescue pattern for the CoA pathway metabo-
lites was also assessed. Amb4317088-treated late stage
gametocytes were successfully rescued to above 100% of
untreated control levels by supplementation of either
CoA or dP-CoA (ANOVA: F(2,11) = 1,932, P < 0.001;
Tukey’s multiple comparisons test P < 0.001; Additional
file 1: Table S2), thus confirming PPAT or DPCK as pu-
tative targets, as postulated regarding the other two
parasite stages tested.
Similar to the observations in asexual blood stages and
early stage gametocytes, STK740987 activity was coun-
teracted in both dP-CoA and CoA-supplemented sam-
ples, albeit to lower rescue levels of approximately 50%
(ANOVA: F(2,11) = 289.8, P < 0.001; Tukey’s multiple
comparisons test P < 0.001; Additional file 1: Table S2).
This is consistent with the compound targeting either
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PPAT or DPCK and possibly the presence of an add-
itional late stage gametocyte specific target.
Interestingly, Amb180780 treatment was rescued by
dP-CoA and CoA (ANOVA: F(2,11) = 823.7, P < 0.001;
Tukey’s multiple comparisons test P < 0.001), but not by
pantethine addition in late stage gametocytes, in contrast
to asexual and early stage gametocyte cultures (Add-
itional file 1: Table S2), possibly indicating a lack of up-
take or utilization of pantethine in these late gametocyte
development stages.
Rescue of CoA pathway intermediates in T. b. brucei
To ascertain whether the active compounds, Amb
4317088, Amb3377585 and STK740987, affected the
CoA synthesis pathway in T. b. brucei, supplementation
of the pathway’s end-product, CoA, was tested. For all
three compounds, CoA supplementation was able to
rescue trypanosome numbers to between 70 ± 11% and
95 ± 4%, compared to untreated control values (ANOVA
F(2,13) = 284.9, 101.5 and 391.5, respectively, P < 0.001;
Additional file 1: Table S2). This observation confirms
that all three inhibitors act on the CoA synthesis path-
way or CoA utilization in T. b. brucei, as previously
demonstrated for P. falciparum [22], and that this path-
way offers opportunity for trypanocidal drug discovery.
As observed in P. falciparum, the growth-inhibitory
activity of Amb4317088 and STK 740987 could also be
rescued by supplementation of dP-CoA, but none of the
other intermediates (Additional file 1: Table S2), indicat-
ing PPAT or competitive inhibition of DPCK as the most
likely target candidates in T. b. brucei. For Amb3377585,
besides the rescue by CoA and dP-CoA, pantothenate
supplementation showed a slight, yet statistically signifi-
cant (within 99.9% CI using Tukey’s multiple compari-
son test) 34 ± 1% rescue of T. b. brucei parasite
numbers, whilst no pantothenate rescue had been ob-
served for this compound in P. falciparum.
Cytotoxicity
An initial indication of compound selectivity over
human cells had previously been obtained through com-
parison of the compounds’ IC50 values against P. falcip-
arum asexual stages and HEK293 [22]. In the present
study, the selectivity investigation was extended to a
small panel of human cancer cell lines, namely the estro-
gen receptor (ER)-positive breast cancer cell line MCF7,
the ER-negative MDA-MB-231, as well as the human
prostate cancer line, PC-3. Additionally, the cytotoxic ef-
fects on mouse embryonic fibroblast cell line 3T3, which
serves as the host cell for T. cruzi in our image-based
amastigote assay, were investigated [35].
Three of the compounds, namely MMV665980, STK
740987 and Amb180780 showed no or only negligible
cytotoxicity against any of the cell lines investigated in
this study, up to the highest tested concentration of
40 μM (Additional file 1: Table S4). These compounds
had not shown cytotoxicity against HEK293 cells and,
with the exception of the weak MMV665980, all the
compounds had shown high activity against P. falcip-
arum asexual blood stages and high selectivity indices in
our previous study [22]. Of the remaining compounds,
Amb3377585 and STK 668036 showed moderate inhibi-
tory activity against all the cancer cell lines examined,
with IC50 ranges of 5–9 μM and 3–5 μM (Additional file
1: Table S4). Although these compounds both inhibited
HEK293 cells with similar potency in our previous study,
they maintained acceptable parasite selectivity indices of
18 and 9, respectively [22].
The compounds Amb4317088 and MMV665820 dis-
played significant activity against the panel of cancer cell
lines tested in this study, with IC50 values ranges of
0.87–4.6 μM and 0.27–0.43 μM, respectively (Additional
file 1: Table S4). The inhibition plateau levels of the
concentration-response curves for the latter compound,
however, were well below 100% inhibition (ranging be-
tween 43% in MDA-MB-231 cells and 80% in PC-3 cells;
Additional file 1: Figure S3). When only a sub-lethal
plateau is reached, the calculated flex point of the
concentration-response curve does not represent the
concentration at which 50% of cells are inhibited, there-
fore it does not represent the true IC50 value of com-
pound activity. This was previously observed in HEK293
cells, as well, and calculated IC50 values for this com-
pound are to be considered approximates. Amb4317088
and MMV665820 had previously shown negligible or
minor selectivity for P. falciparum over HEK293 cells,
with SI values of 1.9 and ~6, respectively [22], thus are
not considered worthwhile candidates to pursue.
The determination of cytotoxicity against the mouse
3T3 cells, necessary for the validation of the T. cruzi
amastigote assay data, showed a similar sensitivity profile
of these cells to that of the HEK293 reference cells pub-
lished earlier [22], with the exception of STK 668036, to
which the 3T3 mouse cells showed a lower susceptibility
than any other cell line tested.
Discussion
The open access MMV malaria box, a collection of
diverse compounds with reported inhibitory activity
against P. falciparum asexual stages, has been tested
against several specific Plasmodium targets and path-
ways [40–43]. Furthermore, the collection was re-
purposed to test efficacy of the compounds against a
broad variety of parasites, including other apicomplexan
parasites such as Cryptosporidium parvum and Toxo-
plasma gondii [44], the kinetoplastids T. b. rhodesiense,
T. b. brucei and T. cruzi [45], the amoebozoa Entamoeba
histolytica [37] and even helminths, such as Schistosoma
Fletcher et al. Parasites & Vectors  (2016) 9:589 Page 6 of 13
mansoni [46]. This broad availability of species-specific
data for a small set of compounds is unprecedented, and
gives researchers the opportunity to identify activity pat-
terns across multiple species and assays.
To directly assess the species-specificity of the
previously-identified CoA pathway inhibitors (two from
the MMV malaria box and five from a small in-house
compound library [22]), we tested the same batch of
compounds on T. cruzi and T. b. brucei using our
previously reported assays. Trypanosomes are clinically
important flagellate protozoan parasites of the order
kinetoplastida, which are not closely related to the
apicomplexan P. falciparum. In addition, we tested the
compounds against a small panel of human cancer cell
lines. In recent years, numerous reports have shown that
compounds with antimalarial activity may represent po-
tential anticancer agents, and vice versa [47–49]. The re-
sults obtained were compared to our previous findings
on asexual P. falciparum and HEK293 cells [22]. The ex-
tended cytotoxicity pattern on the three cancer cell lines
generally matched the previous observations on HEK293
cells. Our results suggest a lack of specific anticancer ac-
tivity by the compounds (Additional file 1: Table S4).
For compound MMV665820 it was observed that the
plateau for the CRC curves for all cell lines investigated
were significantly below 100% (Additional file 1: Figure
S3). This could indicate that the cytotoxic effect only im-
pacts on a certain sub-population of these cells, perhaps
as the result of a redundant process existing in mamma-
lian cells, which allows a percentage of the inhibitor-
treated cells to survive. The plateau for P. falciparum
growth inhibition is observed at 100% [22], demonstrat-
ing that the asexual blood-stage parasite forms have no
mechanism that ensures survival of a subpopulation
under MMV665820 treatment.
We observed that the extracellular trypomastigote
forms of both T. b. brucei and T. cruzi were more sensi-
tive to compound treatment than the intracellular amas-
tigote stage of T. cruzi. Further research will be needed
to identify which of many possible reasons cause this dif-
ferent sensitivity. One possible explanation is that CoA
synthesis could be more important in the trypomastigote
life-cycle stage. Another possibility is that the additional
barrier of the mammalian host cell surrounding the
amastigote form might reduce compound penetration,
and therefore result in a lower observed compound
activity in the T. cruzi amastigote assay. Alternatively,
the amastigote stage may be able to scavenge CoA from
the host cell and thus be insensitive to the compound
activity.
To investigate a potential role of CoA biosynthesis for
host to vector transmission of the malaria parasite, we
investigated the activity of our compounds on P. falcip-
arum gametocytes, the sexual stages of P. falciparum,
essential for malaria transmission. In addition to activity
on the asexual blood stages, gametocytocidal activity is
considered highly desirable for any new drug candidate
to progress in the antimalarial drug development pipe-
line [50]. Parasite stage-specificity and gametocytocidal
activity of the compounds was therefore investigated,
utilizing a luciferase-based approach on early stage
(development from stage I to IIb/III [30]) and late stage
(IV to V [51]) gametocytes.
The same luciferase-based assays utilized in this study
were previously used to assess the anti-gametocyte activ-
ity of the MMV malaria box compounds [30, 51]. In our
prior work we used a screening concentration of 5 μM
and a threshold of 50% activity to select hits to be pro-
gressed for dose-response evaluation. Of the two malaria
box compounds tested in this work, MMV665980 had a
gametocytocidal activity lower than the hit threshold, and
was therefore not previously tested in dose-response. The
other compound, MMV665820, had previously shown a
similar weak inhibition against late stage gametocytes, and
about 50% inhibition at 1 μM against early stage gameto-
cytes in dose-response, thus in range (about 2.3-fold
change) with the present study.
Whilst most of the compounds investigated showed
similar activities against asexual blood stage P. falciparum
and early stage gametocytes, two compounds, STK740987
and Amb180780, were additionally able to inhibit the
viability of late stage gametocytes with similar sub-
micromolar potency. Another compound, Amb4317088,
showed low micromolar IC50 values against all three de-
velopment stages tested. Our observations are consistent
with active CoA synthesis being required in all three P.
falciparum development forms investigated. The lower
susceptibility of late stage gametocytes to most of the
compounds, however, suggests that different levels of CoA
synthesis or utilization are required during the progression
of P. falciparum sexual development. This is consistent
with metabolomic studies showing important metabolic
differences between asexual and gametocyte stages [28], as
well as during the course of gametocyte development [27].
Late stage gametocytes might have a lower basal require-
ment for CoA synthesis and/or utilization, either due to
their terminal differentiation or potentially due to previous
accumulation of sufficient CoA for maintenance of most
of their metabolic functions. Alternatively, the late stage
gametocyte or its RBC host cell might experience changes
in membrane permeability affecting the uptake and/or
efflux of some inhibitors. However, even late stage
gametocytes were unable to tolerate 72 h exposure to ef-
fective CoA synthesis inhibitors like STK740987 and
Amb180780, indicating that these compounds have a
promising transmission blocking potential. Additionally,
these two compounds displayed a favorable low cytotox-
icity profile for all mammalian cell lines tested in our
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study. It would therefore be of interest to confirm the
transmission blocking ability of these compounds by ex-
perimentally infecting mosquitoes with inhibitor-treated
gametocytes (membrane feeding assay). Our investigation
of the deformability of red blood cells infected with late
stage gametocytes in conjunction with viability data, sug-
gested that the observed deformability changes were either
coincident with parasite death or a secondary effect of
killing. Therefore, we could not find evidence of an
independent effect on RBC deformability due to treatment
with the CoA pathway inhibitors.
To probe directly the inhibitory activity of the
compounds on the first step of the P. falciparum CoA
synthesis pathway, we have utilized a radiometric
phosphorylation assay, which allows measurement of
pantothenate phosphorylation by PanK present in P. fal-
ciparum lysates [16, 39]. Only one compound, STK
668036, showed a statistically significant PanK inhibition
of 93 ± 9% at a very high compound concentration
(100 μM), compared to the whole cell activity of 1.3 μM
IC50 on asexual blood stage P. falciparum. Since the par-
asites treated with the compound were rescued by
addition of CoA or dephospho CoA, this weak inhibition
of PanK points to other enzyme(s) of the pathway being
the main target(s) for the compound, whereas the ob-
served activity on PanK was possibly a non-specific off-
target effect observed only at the higher concentrations
of compound. This hypothesis is also supported by our
observation that at high concentrations STK 668036 also
inhibited other kinases in P. falciparum lysates.
To allow the generation of hypotheses regarding the
inhibitors’ possible targets, given the current absence of
enzymatic assays to directly assess inhibition of the sub-
sequent steps of the CoA biosynthesis pathway, we
utilized several pathway intermediates (panthotenate,
panthetine, dephospho CoA and the final product CoA)
as rescuing agents in our rescue assay.
To be able to utilize an intermediate, the parasite first
has to be able to take it up from the surrounding
medium. Eukaryotic cells readily take up and transform
the CoA precursor 4′-phosphopantetheine [52] into
CoA. In the case of P. falciparum, this task is made
more difficult by the fact that the parasite is surrounded
by the outer RBC membrane and the parasitophorous
vacuole membrane. Our experiments suggest that all
three P. falciparum developmental stages examined are
able to take up and utilize CoA, as well as dP-CoA, as
demonstrated by the ability of these intermediates to res-
cue parasite growth in the presence of the investigated
CoA pathway inhibitors.
Since T. b. brucei is not closely related to P. falcip-
arum, it was important to confirm whether the active
compounds were also affecting the CoA synthesis path-
way in this parasite. The growth inhibitory effects of all
three compounds that had shown high activity against T.
b. brucei could be rescued by addition of both CoA and
dP-CoA. This rescue pattern was the same as observed
in P. falciparum, which implies that the same targets in
the CoA synthesis pathway may be affected. The fact
that the inhibitors are not equally active on the different
parasite species could indicate a different accumulation
of inhibitor by different parasites, or structural differ-
ences in their target enzymes.
We also utilized the dimer pantethine in our rescue
experiments based on the hypothesis that P. falciparum
might possess a similar by-pass of its CoA synthesis
pathway as bacteria, which are able to convert pantethine
to pantetheine and further to 4′phosphopantetheine [38].
The fact that the growth inhibitory action of the test com-
pound Amb180780 was successfully rescued by pantethine
supplementation supports this hypothesis. Our findings
are the first preliminary indication that asexual P. falcip-
arum parasites, like bacteria, are able to take up and
utilize the pantethine to synthesize CoA.
Early stage gametocytes treated with Amb180780 were
also rescued by pantethine supplementation, but late
stage gametocytes were not. It seems unlikely that the
target of the compound would change between the two
gametocyte development stages, therefore this lack of re-
sponsiveness to pantethine could indicate that the late
stage gametocytes are either unable to take up pan-
tethine from the medium or that they lack the ability to
convert it into the intermediate 4′phosphopantetheine.
None of the compounds that showed activity against T.
b. brucei were rescued by pantethine supplementation.
However, the activity of the same compounds was also
not susceptible to pantethine supplementation in P.
falciparum. Therefore, no conclusion can be drawn at
this stage regarding whether trypanosomes are able to
utilize pantethine for CoA synthesis.
We also observed that notably higher pantethine con-
centrations were tolerated by early and late stage game-
tocytes (up to 10 mM concentration showing no toxic
effect) compared to asexual blood stage P. falciparum
(IC50 value of 5 mM) or T. b. brucei (IC50 value of
1.2 mM). It would be interesting to investigate further
the mechanism of pantethine uptake in the different P.
falciparum development stages, since a potential vari-
ation in the uptake or elimination mechanism for this
intermediate could also affect the transmembrane
transport of other molecules. Reduced sensitivity of ga-
metocytes to compounds active against blood-stage P.
falciparum parasites has frequently been observed [29,
30, 53], therefore the investigation of stage specific dif-
ferences, as observed here, might reveal novel routes for
targeted intervention.
Interestingly, a recent study on dihydroartemisinin-
induced dormant ring stages of P. falciparum showed
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that these metabolically inactive parasite forms still
maintain active fatty acid synthesis [54]. This observa-
tion implies that such dormant ring forms are likely to
have a continuing requirement for CoA, which is an es-
sential cofactor in fatty acid synthesis. This opens the
possibility that potent, specific P. falciparum CoA synthe-
sis inhibitors could in future be utilized to help to reduce
the recrudescence from dormant parasite forms. Such an
application of P. falciparum CoA synthesis inhibitors
could have clinical implications, since dormant parasite
forms are currently an important concern regarding
the failure of artemisinin combination therapies [54].
Pantothenate uptake is essential for asexual P. falcip-
arum survival [55]. In our investigation, none of the
tested compounds were rescued by pantothenate
addition, excluding the possibility of the compounds be-
ing competitive inhibitors of pantothenate transport,
while non-competitive inhibition remains a possibility.
The evidence provided in this work suggests that the
investigated compounds affect P. falciparum and T. b.
brucei CoA biosynthesis, albeit with various degrees of
specificity, warranting further confirmation. The chem-
ical diversity of the compounds is surprising if a single
target pathway is hypothesized. Recent evidence, how-
ever, has shown that antimalarial compounds belonging
to chemically unrelated classes may share the same mo-
lecular target [56–59].
Recombinant expression of the CoA synthesis enzymes
would be of great value for use in specific enzyme-
coupled activity assays to test compounds directly.
Having the molecular structures of these enzymes would
also allow the use of computational modeling and
docking studies, to gain more detailed insight into the
compound-target interactions and to facilitate inter-
species comparison.
Conclusions
In this work we carried out a biological profiling of pre-
viously identified asexual P. falciparum stage inhibitors
against the sexual stages of the parasite, as well as the
kinetoplastid parasites T. cruzi and T. b. brucei and can-
cer cell lines. We demonstrate for the first time that the
malaria parasite’s gametocytogenesis, like its asexual
replication, relies on CoA. Two of the candidate com-
pounds exhibited sub-micromolar potencies across all
Plasmodium stages tested. Furthermore, three com-
pounds inhibited the viability of T. cruzi and T. b. brucei
trypomastigotes with sub-micromolar potencies. By ex-
posing the parasites to various intermediates of the CoA
synthesis pathway, we could confirm that the active
compounds act on P. falciparum and T. b. brucei CoA
synthesis, and provided support for the hypothesis that
the CoA synthesis pathway is a valuable new drug target
in these parasite species.
Methods
Chemical compounds
The compounds MMV665820 and MMV665980 are part
of the Medicines for Malaria Venture (MMV) Malaria Box,
kindly provided by MMV. The compounds Amb4317088
(Ambinter), STK 668036 (Interchim), STK 740987 (Vitas
M), Amb3377585 (Ambinter) and Amb180780 (Ambinter)
were originally identified from the screening of a library
consisting of structurally diverse, commercially available
compounds. For this work, solids were repurchased from
various suppliers, as indicated in brackets above. The
chemical structures of the study compounds are shown in
Additional file 1: Table S1. All compounds were prepared
as 10 mM 100% DMSO stocks, from which the compounds
were diluted to the respective final assay concentration (see
below for each assay).
Cytotoxicity assay
Cytotoxicity of the compounds was assessed against a
panel of human cancer cell lines, namely the estrogen
receptor (ER)-positive breast cancer cell line MCF7, the
ER-negative MDA-MB-231 and the prostate cancer line
PC-3. All the cell lines were purchased from ATCC and
maintained as previously described [60, 61]. Two bio-
logical replicates consisting of two technical replicates
each were performed to generate concentration response
curves (CRC) with a final highest concentration of
40 μM. A resazurin-based assay was utilized to deter-
mine cell viability as described earlier [22]. Additionally,
the cytotoxic effects on the mouse embryonic fibroblast
cell line 3T3 were assessed as part of the Trypanosoma
cruzi amastigote image-based assay as outlined in [35].
Trypanosoma cruzi amastigote assay
Compound activity against T. cruzi amastigotes was
assessed in an image-based assay in single point
concentration-response and three biological replicates,
at a final highest compound concentration of 47.3 μM,
as previously described [35].
T. cruzi trypomastigote assay
Compound activity against T. cruzi trypomastigotes was
assessed in two independent experiments, without tech-
nical repeats, at a final highest compound concentration
of 40 μM in concentration-response PrestoBlue assay, as
previously described [35].
Trypanosoma brucei brucei assay
Compound activity against T. b. brucei was assessed in a
resazurin-based viability assay in concentration-response
assays, without technical repeats, in two experimental
replicates at a highest concentration of 40 μM, as previ-
ously described [36].
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Gametocyte luciferase assay
Induction of P. falciparum gametocyte differentiation and
gametocyte culturing were performed as previously de-
scribed [62]. Compound activity against early stage gameto-
cytes (covering the development from stage I to IIb/III) and
late stage gametocytes (stage IV to V) of the recombinant
P. falciparum line NF54Pfs16 was assessed in concentration-
response assays, in two experimental replicates consisting
of two technical repeats each, at a highest concen-
tration of 40 μM, as described earlier [30, 51].
Deformability of gametocyte-infected red blood cells
Compound impact on the deformability profile of red
blood cells (RBCs) infected with stage V gametocytes of
the recombinant P. falciparum line NF54Pfs16 was
assessed in two biological replicates in two technical re-
peats each, using an optimized method of that previously
described by Duez et al. [34]. In short, calibrated micro-
spheres of sizes 25–45 μm (type 6) and 5–15 μm (type
3) (solder powder AMTech®,
Deep River, CT, USA) were each mixed separately in
PBS (Sigma-Aldrich, Sydney, Australia) supplemented
with 10 mg/ml Albumax II (Life Technologies, Carlsbad,
CA, USA) and were sequentially deposited into 384 well
filter bottom plates (Seahorse Bioscience, North Biller-
ica, MA, USA). Stage V gametocyte cultures at day 11
post-induction (24 h incubation) or day 12 post-
induction (2 h incubation), obtained as previously
described [62], were dispensed into 384 well plates
(Axygen®) at 0.5% hematocrit and ~5% gametocytemia
and incubated at 37 °C with 90% N2, 5% CO2, 5% O2
with compounds for the indicated exposure durations.
Compounds were tested in concentration-response as-
says at a final highest concentration of 40 μM, in two
biological replicates, without technical repeats. Post in-
cubation, samples were resuspended and loaded into
microsphere filter plates and vacuum aspirated into the
microsphere matrix. Then, wash buffer (gametocyte
growth medium without N-acetyl-D-glucosamine) was
added followed by vacuum aspiration into a 384 well
storage plate. After microsphere filtration, c.100,000
cells/well were transferred to imaging plates (Perkin
Elmer cell carrier) containing PBS and CellMask™ orange
1:15,000 (Invitrogen, Carlsbad, CA, USA) and imaged
12–24 h later using an Opera confocal high content im-
aging system (Perkin Elmer) with 20× magnification.
Ten fields per well were acquired resulting in > 10,000
RBCs/well being analysed using Opera® Columbus soft-
ware (to quantify RBCs and gametocytes). Retention
rates were calculated as described previously [34].
Pantothenate kinase assay
The ability of the test compounds to inhibit P. falcip-
arum pantothenate kinase (PfPanK) was assessed with a
radiometric pantothenate phosphorylation assay as de-
scribed previously [39]. In short, the phosphorylation of
[14C] pantothenate by P. falciparum lysates was mea-
sured in the presence or absence of a single concentra-
tion (100 μM, two biological replicates in duplicate
technical repeats) of each test compound. Additionally,
the activity of STK 668036 on PfPanK and two add-
itional parasite kinases, namely hexokinase (PfHK), and
choline kinase (PfChK), was tested at 2, 10 and 100 μM
compound concentration, in two independent experi-
ments. P. falciparum lysate was prepared from tropho-
zoite stage parasites isolated from their host RBC by
treatment with 0.05% (w/v) saponin, and washed (three
times) in HEPES-buffered saline (125 mM NaCl, 5 mM
KCl, 20 mM D-glucose, 25 mM HEPES, 1 mM MgCl2,
pH 7.1). Lysates were prepared in 10 mM potassium
phosphate, pH 7.4, the concentration of cell lysates was
determined from cell counts with an improved
Neubauer hemocytometer, and aliquots of lysate were
stored at -20 °C.[14C] pantothenate, [14C] 2-deoxyglucose
and [14C] choline phosphorylation were assayed using
Somogyi reagent as described earlier [39].
Chemical rescue with CoA pathway intermediates
The P. falciparum luciferase and T. b. brucei assays de-
scribed above were modified by adding CoA pathway
metabolites (pantothenate, pantethine, dP-CoA and
CoA) to allow assessment of chemical rescue. An im-
aging based assay was utilised to assess the chemical res-
cue on asexual stages of P. falciparum as described
previously [22]. All the pathway intermediates were pur-
chased from Sigma. CoA and dP-CoA were dissolved in
sterile distilled water to obtain a 20 mM stock solution,
which was then aliquoted and stored at -20 °C until use.
Pantothenate and pantethine were prepared freshly be-
fore use from solids. Each pathway intermediate was
tested on the parasites at a range of concentrations to
assess potential toxicity. The final concentration ranges
were 10 mM to 78 μM in 8 serial dilution steps for
pantothenate; 10 mM to 1.2 μM in 16 serial dilution
steps for pantethine; 2 mM to 0.6 mM in 8 dilutions
steps of 0.2 mM increments for CoA. On early stage P.
falciparum gametocytes the same concentrations as for
CoA were tested for dP-CoA; against asexual blood stage
P. falciparum, late stage gametocytes and Trypanosoma
b. brucei five dP-CoA concentrations were tested
(2 mM, 1.5 mM, 1 mM, 0.75 mM and 0.5 mM).
The same concentration ranges of the CoA pathway
intermediates were supplemented to parasites treated
with the experimental compounds. The inhibitors were
used at their respective final assay concentration of IC80
(as determined previously in the corresponding P.
falciparum development stage or T. b. brucei assay). Due
to varying toxicity and effectiveness of the intermediates
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on the various parasites and life-cycle stages tested,
the best rescue concentration was determined indi-
vidually for each intermediate on each parasite or
parasite stage. The concentrations that provided the
best rescue results (as reported in Additional file 1:
Table S2) were the following: Pantothenate, 300 μM
on asexual P. falciparum blood stages, 625 μM on
early and 312.5 μM on late stage gametocytes,
1.25 mM on T. b. brucei; pantethine, 125 μM on
asexual P. falciparum blood stages, 10 mM on early
and 5 mM on late stage gametocytes, 2.44 μM on T.
b. brucei; dP-CoA, 0.8 mM on asexual P. falciparum
blood stages, 1.2 mM on early and 2 mM on late
stage gametocytes, 1.6 mM on T. b. brucei; CoA 0.8 mM
on asexual P. falciparum blood stages, 1.6 mM on early
and 1.8 mM on late stage gametocytes, 1.0 mM on T. b.
brucei. The negative control used in each assay was 0.4%
DMSO, whilst the positive control was 2 μM artemisinin
for asexual P. falciparum blood stages and 5 μM puro-
mycin for all gametocyte stages and T. b. brucei. The per-
centage growth of the respective parasites following
compound treatment was determined using Microsoft ®
Excel 2010, and compared with their controls. All rescue
assays were performed as two independent experiments
each in duplicate point.
Statistical analysis
Statistical analysis and graphical output were performed
in GraphPad Prism® v.5. CRC fitting was carried out by
employing a variable slope, 4 parameter non-linear regres-
sion analysis. One way ANOVA and Tukey’s multiple
comparison test were used to assess the significance of the
rescue with supplementation of metabolites versus com-
pound treatment alone.
Additional file
Additional file 1: Figure S1. Retention of gametocyte-infected RBCs
after treatment for 2 h (light grey dots) or 24 h (dark grey triangles) with
compound concentrations ranging from 10 μM to 0.1 nM. Viability of
compound treated gametocytes assessed with Mitotracker Red (MTR),
shown as black squares. For all tested compounds, any increased reten-
tion rates observed coincided with parasite death, therefore no specific
RBC deformability change due to compound treatment could be deter-
mined. Figure S2. Effect of test compounds on kinase activity using a
radiometric assay (n = 2). (A) Activity of all compounds on PanK at
100 μM; (B) activity of STK668036 on three kinases: PanK, Hexokinase
(HK) and Choline kinase (ChK). Asterisks indicate a significant level of in-
hibition, compared to the control (P < 0.001). Error bars represent stand-
ard deviations. Table S1. Activity overview against P. falciparum asexual
blood stage forms, early and late stage gametocytes, as well as T. b. brucei
and T. cruzi. Table S2. Rescue of inhibitor-treated asexual blood stage P.
falciparum, early stage and late stage P. falciparum gametocytes and T. b.
brucei trypomastigotes by supplementation with CoA pathway intermedi-
ates. Percent rescue averages ± SEM. The rescue experiment was not car-
ried out for inactive compounds (blank spaces). All numeric values are
statistically significant (P < 0.001). Table S3. Activity of MMV000570
against Trypanosoma spp., cytotoxicity against a panel of
cell lines and selectivity indices (A); the activity of MMV000570 against P.
falciparum asexual stages and early stage gametocytes could not be res-
cued by CoA pathway metabolites; percent rescue averages ± SEM (B).
Table S4. Cytotoxicity of test compounds on human cancer cell lines
in comparison with reference cell lines and antiplasmodial activity.
Figure S3. Concentration response curves displaying cytotoxic effect of
MMV665820 on the four mammalian cell lines MCF7 (A), MDA-MB-231
(B), PC3 (C) and 3 T3 (D). (PDF 905 kb)
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